Filing Flows

Filing Flows › Companies › Silence Therapeutics › Cash flow

Silence Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$1.5M in Q2 2026 · −$42.3M over twelve months

Operating cash flow$1.5M
Free cash flow+$1.5M

Analysis

In Q2 2026, Silence Therapeutics generated $1.5M of operating cash flow. That is $23.4M more than in Q2 2025 (−$21.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$42.3M; the largest uses were operating cash flow ($42.3M), capital spending ($3K); besides operations, cash came from other investing ($72.9M), shares issued ($2K); the cash balance rose by $30.3M.

Operating cash flow was $1.5M against net income of −$12.3M. The largest differences: prepaid and other assets −$2.3M, stock-based pay +$1.3M, depreciation & amortization +$73K.

Free cash flow

Silence Therapeutics: free cash flow by quarterSilence Therapeutics: free cash flow by quarter−$25.7MQ3 2024−$27.5MQ4 2024−$12.3MQ1 2025−$21.8MQ2 2025−$10.9MQ3 2025−$17.3MQ4 2025−$15.6MQ1 2026$1.5MQ2 2026
Operating cash flow less capital spending.
Silence Therapeutics: operating cash flow against capital spendingSilence Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$25.6M$64KQ3 2024−$27.5M$62KQ4 2024−$12.3M$4KQ1 2025−$21.8M$48KQ2 2025−$10.9M$3KQ3 2025−$17.3M$0Q4 2025−$15.6M$0Q1 2026$1.5M$0Q2 2026
Latest (Q2 2026): Operating cash flow $1.5M, Capital spending $0.

Capital allocation, year by year

Silence Therapeutics: where the cash came from (up) and went (down), by fiscal yearSilence Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2022: Operating cash flow −$57.0MFY2022: Shares issued $52.6MFY2022: Capital spending −$173K$52.6MFY2022FY2023: Operating cash flow −$49.5MFY2023: Shares issued $31.9MFY2023: Capital spending −$56K$31.9MFY2023FY2024: Operating cash flow −$67.6MFY2024: Shares issued $142MFY2024: Capital spending −$211K$142MFY2024FY2025: Operating cash flow −$62.3MFY2025: Shares issued $15KFY2025: Capital spending −$55K$15KFY2025
Over these 4 years operating cash flow totalled −$236M; the largest uses were operating cash flow ($236M) and capital spending ($495K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$72.1M
Debtnone
Net cash$72.1M
Cash runway20 months

Silence Therapeutics is burning cash: its operations consume cash, a free cash flow of −$42.3M a year at the current rate against $72.1M of cash and investments: a runway of about 20 months before any new financing.

Where the cash came from and went

Silence Therapeutics: sources (+) and uses (−) of cash, Q2 2026Silence Therapeutics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)−$66.4MOther investing$64.9MOperating cash flow$1.5MExchange rates−$63KShares issued$2K
Silence Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Silence Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$72.9MOperating cash flow−$42.3MCash drawn (+) / kept (−)−$30.3MExchange rates−$315KCapital spending−$3KShares issued$2K

From profit to cash

Silence Therapeutics: net income to operating cash flow, Q2 2026Silence Therapeutics: net income to operating cash flow, Q2 2026Net income−$12.3MDepreciation & amortization$73KStock-based pay$1.3MPrepaid and other assets−$2.3MOperating cash flow$1.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$1.5M—$2K−$66.4M$1.5M
Q1 2026−$15.6M——$5.6M−$15.6M
Q4 2025−$17.3M——$70.8M−$17.3M
Q3 2025−$10.9M−$3K—−$40.3M−$10.9M
Q2 2025−$21.8M−$48K$1K$23.1M−$21.8M
Q1 2025−$12.3M−$4K$14K$56.4M−$12.3M
Q4 2024−$27.5M−$62K−$98K−$38.4M−$27.5M
Q3 2024−$25.6M−$64K$8.0M$55.5M−$25.7M

Silence Therapeutics: income statement and cash flow

Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year). The chart follows the revenue to costs, profit and cash.

Silence Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.